Arkuda Therapeutics
Arkuda Therapeutics: Pioneering neurodegenerative disease treatments through innovative biotechnology.
Founded
2018Arkuda Therapeutics: Pioneering neurodegenerative disease treatments through innovative biotechnology.
Arkuda Therapeutics is a biotechnology company dedicated to developing innovative medicines aimed at altering the progression of neurodegenerative diseases. Leveraging their specialized expertise in progranulin and lysosomal biology, Arkuda focuses on creating treatments for conditions such as Alzheimer's Disease, Parkinson's Disease, and frontotemporal dementia (FTD). Their mission is to bring new therapeutic options to those affected by these debilitating diseases, ultimately aiming to improve patients' lives.
Arkuda Therapeutics has made significant strides in the field of neurodegeneration, utilizing cutting-edge research and insights into lysosomal biology. Their pioneering approach has positioned them as a key player in the development of novel treatments that could potentially change the course of neurodegenerative diseases. The company's impact is marked by its commitment to translating scientific discoveries into practical therapies that offer hope and improved outcomes for patients worldwide.
Companies similar to Arkuda Therapeutics include Lysosomal Therapeutics, Denali Therapeutics, Aprinoia Therapeutics and Endlyz Therapeutics.
Arkuda Therapeutics was founded in 2018.
Arkuda Therapeutics' headquarters is located in Watertown, MA, US.
Arkuda Therapeutics' most recent funding round was for $64M (USD) in February 2022.
As of Feb 10, 2022, Arkuda Therapeutics has disclosed funding of $108M (USD). Undisclosed round amounts are excluded.
Arkuda Therapeutics has 30 employees as of Feb 4, 2024.
Endlyz Therapeutics
